{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:00:18Z","timestamp":1780923618822,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005977","name":"Kaiser Permanente","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.drudis.2025.104542","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:30:04Z","timestamp":1763641804000},"page":"104542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discovering a transformative cancer drug: the case of ibrutinib"],"prefix":"10.1016","volume":"30","author":[{"given":"Liam","family":"Bendicksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8867-2666","authenticated-orcid":false,"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104542_b0005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104542_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41571-023-00821-7","article-title":"Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma","volume":"21","author":"Cliff","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0015","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.drudis.2025.104542_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104542_b0025","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.drudis.2025.104542_b0030","unstructured":"Love J. Notes on clinical studies for Imbruvica\/ibrutinib. Knowledge Ecology International. Published 2 October 2023. Accessed 11 October 2025. https:\/\/www.keionline.org\/wp-content\/uploads\/KEI-BN-2023-3.pdf."},{"key":"10.1016\/j.drudis.2025.104542_b0035","unstructured":"Johnson & Johnson. Johnson & Johnson reports Q4 and full-year 2023 results. Published 23 January 2024. Accessed 11 October 2025. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-reports-q4-and-full-year-2023-results."},{"key":"10.1016\/j.drudis.2025.104542_b0040","unstructured":"AbbVie. AbbVie reports full-year and fourth-quarter 2023 financial results. Published 2 February 2024. Accessed 11 October 2025. https:\/\/investors.abbvie.com\/news-releases\/news-release-details\/abbvie-reports-full-year-and-fourth-quarter-2023-financial."},{"key":"10.1016\/j.drudis.2025.104542_b0045","unstructured":"Raymakers AJN, Kesselheim AS, Rome BN. Medicare price negotiation: the example of ibrutinib. Health Affairs Forefront. Published 2 May 2023. Accessed 11 October 2025. https:\/\/www.healthaffairs.org\/content\/forefront\/medicare-price-negotiation-under-inflation-reduction-act-example-ibrutinib."},{"key":"10.1016\/j.drudis.2025.104542_b0050","unstructured":"US Department of Health and Human Services. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2026. Published 15 August 2024. Accessed 11 October 2025. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026."},{"key":"10.1016\/j.drudis.2025.104542_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7467","article-title":"Trends in Medicare spending on oral drugs for chronic lymphocytic leukemia from 2014 to 2020","volume":"6","author":"Cliff","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2025.104542_b0060","unstructured":"Lovelace B Jr., Tirrell M. Some cancer patients forgo life-saving medications because of high cost. NBC News. Published 9 July 2022. Accessed 11 October 2025. https:\/\/www.nbcnews.com\/health\/health-news\/cost-cancer-drugs-patients-dont-fill-cancer-drug-prescriptions-high-co-rcna36793."},{"key":"10.1016\/j.drudis.2025.104542_b0065","unstructured":"US House of Representatives Committee on Oversight and Reform. Drug pricing investigation: AbbVie\u2013Humira and Imbruvica. Published May 2021. Accessed 11 October 2025. https:\/\/oversightdemocrats.house.gov\/sites\/evo-subsites\/democrats-oversight.house.gov\/files\/Committee%20on%20Oversight%20and%20Reform%20-%20AbbVie%20Staff%20Report.pdf."},{"key":"10.1016\/j.drudis.2025.104542_b0070","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1377\/hlthaff.2021.01742","article-title":"Many Medicare beneficiaries do not fill high-price specialty drug prescriptions","volume":"41","author":"Dusetzina","year":"2022","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.drudis.2025.104542_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104542_b0080","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2025.104542_b0085","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.drudis.2016.05.001","article-title":"Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development","volume":"21","author":"Caplan","year":"2016","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104542_b0090","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.drudis.2020.09.024","article-title":"Public funding for transformative drugs: the case of sofosbuvir","volume":"26","author":"Barenie","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104542_b0095","article-title":"Betting on hepatitis C: how financial speculation in drug development influences access to medicines","volume":"354","author":"Roy","year":"2016","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2025.104542_b0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104542_b0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-F","article-title":"Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia","volume":"72","author":"Tsukada","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104542_b0110","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.20042101","article-title":"Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells","volume":"201","author":"Feldhahn","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104542_b0115","unstructured":"Hensley S. Celera to buy Axys for $174 million; move bolsters drug-production plans. Wall Street Journal. Published 14 June 2001. Accessed October 11, 2025. https:\/\/www.wsj.com\/articles\/SB992451561739433508."},{"key":"10.1016\/j.drudis.2025.104542_b0120","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104542_b0125","unstructured":"Herper M. Celera\u2019s about-face. Forbes. Published 22 April 2002. Accessed 11 October 2025. https:\/\/www.forbes.com\/2002\/04\/22\/0422celera.html?sh=689d1c935e1a."},{"key":"10.1016\/j.drudis.2025.104542_b0130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0045-2068(02)00009-3","article-title":"pH dependence of inhibitors targeting the occluding loop of cathepsin B","volume":"30","author":"Cathers","year":"2002","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.drudis.2025.104542_b0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2025.104542_b0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104542_b0145","unstructured":"Celera Genomics announces sale of therapeutic programs to Pharmacyclics. US Securities and Exchange Commission. Published 10 April 2006. Accessed 11 October 2025. https:\/\/www.sec.gov\/Archives\/edgar\/data\/949699\/000094969906000018\/exh99-1.pdf."},{"key":"10.1016\/j.drudis.2025.104542_b0150","unstructured":"Inglis J. Pharmacyclics: first drug gets rolling. Drug Discovery News. Published 8 April 2014. Accessed 11 October 2025. https:\/\/www.drugdiscoverynews.com\/pharmacyclics-first-drug-gets-rolling-8327."},{"key":"10.1016\/j.drudis.2025.104542_b0155","unstructured":"Shaywitz D. The wild story behind a promising experimental cancer drug. Forbes. Published 8 April 2013. Accessed 11 October 2025. https:\/\/www.forbes.com\/sites\/davidshaywitz\/2013\/04\/05\/the-wild-story-behind-a-promising-experimental-cancer-drug\/?sh=4853a9285857."},{"key":"10.1016\/j.drudis.2025.104542_b0160","unstructured":"ATI Advisory. First 10 drugs selected for Medicare negotiation. Published 30 August 2023. Accessed 11 October 2025. https:\/\/atiadvisory.com\/resources\/first-10-drugs-selected-for-medicare-negotiation\/."},{"key":"10.1016\/j.drudis.2025.104542_b0165","unstructured":"Vardi N. For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug. New York: W. W. Norton & Company."},{"key":"10.1016\/j.drudis.2025.104542_b0170","unstructured":"Pharmacyclics, Inc. Cancer drug fails to meet goal in phase 3 trials. BioSpace. Published 19 December 2005. Accessed 11 October 2025. https:\/\/www.biospace.com\/pharmacyclics-inc-cancer-drug-fails-to-meet-goal-in-phase-3-trials."},{"key":"10.1016\/j.drudis.2025.104542_b0175","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104542_b0180","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/jco.2007.25.18_suppl.3600","article-title":"Targeting syk kinase for the treatment of B-cell lymphoma","volume":"25","author":"Sharman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0185","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104542_b0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104542_b0195","doi-asserted-by":"crossref","unstructured":"Pollyea DA et al. A phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay. Poster presented at American Society of Hematology Annual Meeting; 2009 November 20. New Orleans, LA.","DOI":"10.1182\/blood.V114.22.3713.3713"},{"key":"10.1016\/j.drudis.2025.104542_b0200","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104542_b0205","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104542_b0210","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","article-title":"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy","volume":"123","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104542_b0215","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2012.43.3748","article-title":"Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia","volume":"30","author":"Cheson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0220","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0225","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104542_b0230","unstructured":"Collaboration and license agreement by and between Pharmacyclics, Inc. and Janssen Biotech, Inc. US Securities and Exchange Commission. Published 8 December 2011. Accessed 11 October 2025. https:\/\/www.sec.gov\/Archives\/edgar\/data\/949699\/000092189512000285\/ex101to10q07380_02082012.htm."},{"key":"10.1016\/j.drudis.2025.104542_b0235","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104542_b0240","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104542_b0245","unstructured":"Rockoff JD, Loftus P. AbbVie to buy Pharmacyclics in $21 billion deal. Wall Street Journal. Published 5 March 2015. Accessed 11 October 2025. https:\/\/www.wsj.com\/articles\/abbvie-to-buy-pharmacyclics-in-21-billion-deal-1425528086."},{"key":"10.1016\/j.drudis.2025.104542_b0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104542_b0255","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0260","unstructured":"O\u2019Brien S. Ibrutinib CLL Trial: where is the equipoise? ASCO Post. Published 1 May 2013. Accessed 11 October 2025. https:\/\/ascopost.com\/issues\/may-1-2013\/ibrutinib-cll-trial-where-is-the-equipoise\/."},{"key":"10.1016\/j.drudis.2025.104542_b0265","unstructured":"de Claro RA, Kaminskas E, Farrell A, Pazdur R. FDA on CLL drug approval and expanded access. ASCO Post. Published 15 September 2013. Accessed 11 October 2025. https:\/\/ascopost.com\/issues\/september-15-2013\/fda-on-cll-drug-approval-and-expanded-access\/."},{"key":"10.1016\/j.drudis.2025.104542_b0270","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.22.02675","article-title":"Ensuring ethical postprogression therapy for patients in randomized trial control arms","volume":"41","author":"Cliff","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0275","unstructured":"Staton T. J&J, Pharmacyclics slap $130,000 price on Imbruvica for rare lymphoma. Fierce Pharma. Published 14 November 2013. Accessed 11 October 2025. https:\/\/www.fiercepharma.com\/sales-and-marketing\/j-j-pharmacyclics-slap-130-000-price-on-imbruvica-for-rare-lymphoma."},{"key":"10.1016\/j.drudis.2025.104542_b0280","article-title":"A holistic view of innovation incentives and pharmaceutical policy reform","volume":"1","author":"Sachs","year":"2023","journal-title":"Health Aff Sch"},{"key":"10.1016\/j.drudis.2025.104542_b0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071710","article-title":"High drug prices are not justified by industry\u2019s spending on research and development","volume":"380","author":"Angelis","year":"2023","journal-title":"Br Med J"},{"key":"10.1016\/j.drudis.2025.104542_b0290","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15445","article-title":"Costs of drug development and research and development intensity in the US, 2000-2018","volume":"7","author":"Sertkaya","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.drudis.2025.104542_b0295","unstructured":"Pharmaceutical Research and Manufacturers of America. Innovation in the biopharmaceutical pipeline. Published December 2021. Accessed 13 October 2025. https:\/\/cdn.aglty.io\/phrma\/global\/resources\/import\/pdfs\/Innovation_in_Biopharmaceuticals.pdf."},{"key":"10.1016\/j.drudis.2025.104542_b0300","unstructured":"Beilfuss L. AbbVie steps up share buybacks after wrapping up pharmacyclics deal. Wall Street Journal. Published 27 May 2015. Accessed 11 October 2025. https:\/\/www.wsj.com\/articles\/abbvie-steps-up-share-buybacks-after-wrapping-up-pharmacyclics-deal-1432723979."},{"key":"10.1016\/j.drudis.2025.104542_b0305","unstructured":"Somayaji C. Johnson & Johnson plans $10 billion share repurchase program. Bloomberg. Published 13 October 2015. Accessed 11 October 2025. https:\/\/www.bloomberg.com\/news\/articles\/2015-10-13\/johnson-johnson-plans-a-10-billion-share-repurchase-program."},{"key":"10.1016\/j.drudis.2025.104542_b0310","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamaoncol.2021.7987","article-title":"Financial toxicity of cancer treatment","volume":"8","author":"Hussaini","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.drudis.2025.104542_b0315","unstructured":"Johnson CY. Science hinted that cancer patients could take less of a $148\u2005000-a-year drug. Its maker tripled the price of a pill. Washington Post. Published 18 April 2018. Accessed 11 October 2025. https:\/\/www.washingtonpost.com\/news\/wonk\/wp\/2018\/04\/18\/science-hinted-that-cancer-patients-could-take-less-of-a-148000-a-year-drug-the-company-tripled-the-price-of-a-pill\/."},{"key":"10.1016\/j.drudis.2025.104542_b0320","unstructured":"Ratain MJ et al. Sales revenues at the potential expense of patient safety: the example of You&i. The Cancer Letter. Published 13 April 2018. Accessed 11 October 2025. https:\/\/cancerletter.com\/trials-and-tribulations\/20180413_5\/."},{"key":"10.1016\/j.drudis.2025.104542_b0325","unstructured":"Johnson CY. After outcry, drugmakers decide not to triple the price of a cancer pill. Washington Post. Published 15 May 2018. Accessed 11 October 2025. https:\/\/www.washingtonpost.com\/news\/wonk\/wp\/2018\/05\/15\/after-outcry-drugmakers-decide-not-to-triple-the-price-of-a-cancer-pill\/."},{"key":"10.1016\/j.drudis.2025.104542_b0330","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41573-022-00542-z","article-title":"Advances in covalent drug discovery","volume":"21","author":"Boike","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104542_b0335","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/712506","article-title":"Killer acquisitions","volume":"129","author":"Cunningham","year":"2021","journal-title":"J Pol Econ"},{"key":"10.1016\/j.drudis.2025.104542_b0340","unstructured":"Kalindjian A et al. Financial ecosystem of pharmaceutical R&D, Annex A. Published September 2021. Accessed 11 October 2025. https:\/\/www.rand.org\/content\/dam\/rand\/pubs\/external_publications\/EP60000\/EP68954\/RAND_EP68954.annexa.pdf."},{"key":"10.1016\/j.drudis.2025.104542_b0345","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"J Am Med Assoc"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:05:34Z","timestamp":1780920334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":69,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1359644625002557"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104542","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovering a transformative cancer drug: the case of ibrutinib","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104542"}}